Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients

[1]  T. Habuchi,et al.  Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[2]  M. Miura.  Enantioselective disposition of lansoprazole and rabeprazole in human plasma. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[3]  N. Yasui-Furukori,et al.  Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. , 2005, British journal of clinical pharmacology.

[4]  T. Habuchi,et al.  Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. , 2005, Transplantation proceedings.

[5]  T. Habuchi,et al.  Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  A. Munakata,et al.  Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. , 2005, British journal of clinical pharmacology.

[7]  D. Holt,et al.  Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians , 2005, Transplantation.

[8]  T. Habuchi,et al.  Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.

[9]  M. Miura,et al.  Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes , 2004, European Journal of Clinical Pharmacology.

[10]  M. Miura,et al.  Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  P. Beaune,et al.  Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  J. Chun,et al.  Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[13]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[14]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Ji-Young Park,et al.  Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 , 2002, Clinical pharmacology and therapeutics.

[16]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[17]  J. Azuma,et al.  Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.

[18]  K. Ohashi,et al.  Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night‐time in different CYP2C19 genotype groups , 2002, Alimentary pharmacology & therapeutics.

[19]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[20]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[21]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[22]  S. Ishihara,et al.  CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole , 2000, Alimentary pharmacology & therapeutics.

[23]  J. Witte,et al.  CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism , 2000, Clinical pharmacology and therapeutics.

[24]  S. Yamaguchi,et al.  No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. , 1999, Biochemical pharmacology.

[25]  T. Suzuki,et al.  A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. , 1999, Biological & pharmaceutical bulletin.

[26]  C. Nakamura,et al.  Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.

[27]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[28]  U. Christians,et al.  Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[29]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[30]  D. Dunn,et al.  Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. , 1995, Journal of the American College of Surgeons.

[31]  H. Satoh,et al.  Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, The Journal of pharmacology and experimental therapeutics.